Is iRhythm Technologies, Inc. overvalued or undervalued?

As of 15 February 2017, the valuation grade for iRhythm Technologies, Inc. moved from does not qualify to risky. The company appears to be overvalued given its high Price to Book Value of 54.03, a negative EV to EBITDA of -95.35, and a troubling ROE of -76.24%. In comparison, peers such as Globus Medical, Inc. and CONMED Corp. show more attractive valuations with P/E ratios of 18.37 and 19.96, respectively.
Despite a strong year-to-date return of 95.63% compared to the S&P 500's 12.22%, the longer-term performance reveals a concerning trend, with a 5-year return of -24.40% against the S&P 500's 96.61%. This indicates that while recent performance may seem promising, the overall valuation metrics suggest that iRhythm Technologies, Inc. is not justified at its current price level.